adenosine diphosphate ribose has been researched along with Ovarian Neoplasms in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 1 (4.55) | 24.3611 |
| 2020's | 16 (72.73) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, Z; Zhang, J; Zhang, Z | 1 |
| Au-Yeung, G; Freimund, A; Friedlander, M; Krasovitsky, M; Lee, YC; Mileshkin, L; Norris, C; Sivakumaran, T; So, J; Webber, K | 1 |
| Barber, J; Birtle, AJ; Brock, S; Crabb, SJ; Dempsey, L; Enting, D; Faust, G; Frew, J; Gale, J; Hinsley, S; Hussain, S; Jones, RJ; Lees, K; McGovern, U; Parikh, O; Powles, T; Ratnayake, G; Song, Y; Soulis, E; Sundar, S; Trevethan, A | 1 |
| Barberis, M; Betella, I; Bonaldo, G; Colombo, N; Fumagalli, C; Guerini-Rocco, E; Ranghiero, A; Rappa, A; Vacirca, D | 1 |
| Belogurov, AA; Chen, G; Chen, Z; He, Q; Li, X; Lin, S; Liu, Y; Tian, J; Yang, M; Zhang, F | 1 |
| Aprile, G; Candela, MV; Ferrario, L; Giuliani, J; Mantoan, B | 1 |
| Dai, Y; Li, J; Li, Q; Zhang, L; Zhang, S | 1 |
| Coleman, RL; Colombo, N; Dean, A; Denys, H; Esteves, B; Harter, P; Konner, JA; Lorusso, D; Marin, MR; Matulonis, UA; Method, M; Murphy, CG; Noble, E; Oaknin, A; Pignata, S; Van Gorp, T; Wang, J | 1 |
| Burel-Vandenbos, F; Cardot-Leccia, N; Dadone-Montaudié, B; Di Mauro, I; Fabas, T; Gaubert, A; Kervarrec, T; Kubiniek, V; Montaudié, H; Pedeutour, F; Tallet, A | 1 |
| Abe, M; Aida, T; Baba, T; Chiba, Y; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takahashi, F; Takatori, E | 1 |
| Chen, B; Du, N; Gu, L; Ji, J; Jin, Q; Khadaroo, PA; Li, S; Mao, D; Mo, J; Shen, Z; Xie, L | 1 |
| Du, N; Hong, J; Jiang, J; Mao, D; Mo, J; Ng, DM; Shi, H; Xie, L; Yang, Y | 1 |
| Gabrail, N; Smith, C | 1 |
| Bachvarov, D; Bachvarova, M; Gregoire, J; Masson, JY; Navarro, JM; Perez, RB; Plante, M; Renaud, MC; Sebastianelli, A; Sheta, R | 1 |
| Bartoletti, M; Cecere, SC; Musacchio, L; Pignata, S; Puglisi, F; Sorio, R | 1 |
| Li, P; Liu, S; Liu, Y; Wang, D; Wei, W; Yang, H; Zhang, Y | 1 |
| Safra, T | 1 |
| Furui, T; Imai, A; Sugiyama, M; Tamaya, T | 1 |
| Fuseya, T; Horibe, S; Imai, A; Takagi, H; Tamaya, T | 1 |
| Bernges, F; Bürkle, A; Küpper, JH; Zeller, WJ | 1 |
| Emons, G; Gründker, C; Völker, P | 1 |
6 review(s) available for adenosine diphosphate ribose and Ovarian Neoplasms
| Article | Year |
|---|---|
Correlation of poly (adenosine diphosphate[ADP]-ribose) polymerase expression and prognosis in ovarian cancer: A systematic review and meta-analysis.
Topics: Adenosine Diphosphate; Adenosine Diphosphate Ribose; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Ribose | 2022 |
Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
Topics: Adenosine Diphosphate Ribose; DNA Damage; Female; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2023 |
BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature.
Topics: Adenosine Diphosphate Ribose; BRCA1 Protein; BRCA2 Protein; Carcinoma, Merkel Cell; Female; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Skin Neoplasms | 2023 |
Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis.
Topics: Adenosine Diphosphate Ribose; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Enzyme Inhibitors; Female; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Survival; Treatment Outcome | 2020 |
The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
Topics: Adenosine Diphosphate Ribose; Female; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis | 2020 |
Hereditary ovarian cancer: biology, response to chemotherapy and prognosis.
Topics: Adenosine Diphosphate Ribose; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Mutation; Ovarian Neoplasms; Prognosis; Risk Factors; United States | 2009 |
2 trial(s) available for adenosine diphosphate ribose and Ovarian Neoplasms
| Article | Year |
|---|---|
A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
Topics: Adenosine Diphosphate Ribose; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Transitional Cell; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerases; Urinary Bladder Neoplasms | 2023 |
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Topics: Adenosine Diphosphate Ribose; Antineoplastic Agents; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Folate Receptor 1; Humans; Immunoconjugates; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors | 2023 |
14 other study(ies) available for adenosine diphosphate ribose and Ovarian Neoplasms
| Article | Year |
|---|---|
Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.
Topics: Adenosine Diphosphate Ribose; Antineoplastic Agents; Australia; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Retrospective Studies | 2022 |
In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
Topics: Adenosine Diphosphate Ribose; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Feasibility Studies; Female; Formaldehyde; Genomic Instability; Humans; Ovarian Neoplasms; Recombinational DNA Repair; Reproducibility of Results | 2022 |
SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair.
Topics: Adenosine Diphosphate Ribose; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; DNA; Female; Humans; Irinotecan; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Recombinational DNA Repair | 2022 |
Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.
Topics: Adenosine Diphosphate Ribose; Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Female; Humans; Maintenance Chemotherapy; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2023 |
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
Topics: Adenosine Diphosphate Ribose; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies; Thrombocytopenia | 2023 |
[Chinese expert consensus on drug interaction management of poly ADP-ribose polymerase inhibitors].
Topics: Adenosine Diphosphate Ribose; Consensus; Drug Interactions; Female; Humans; Male; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors | 2023 |
Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series.
Topics: Adenosine Diphosphate Ribose; Breast Neoplasms; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Thiazoles; Thiophenes; Thrombocytopenia | 2020 |
Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Topics: Adenosine Diphosphate Ribose; Biomarkers; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors | 2020 |
Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices.
Topics: Adenosine Diphosphate Ribose; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
Quartz Crystal Microbalance Detection of Poly(ADP-ribose) Polymerase-1 Based on Gold Nanorods Signal Amplification.
Topics: Adenosine Diphosphate Ribose; Biomarkers, Tumor; Cell Line, Tumor; Cetrimonium; Female; Gold; Humans; Limit of Detection; NAD; Nanotubes; Neoplasm Proteins; Niacinamide; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly Adenosine Diphosphate Ribose; Quartz Crystal Microbalance Techniques; Static Electricity | 2019 |
Evidence for tight coupling of Gi protein-mediated lysophosphatidic acid receptor to stimulated cytokine production in ovarian cancer cell.
Topics: Adenosine Diphosphate Ribose; Catalysis; Cell Line, Tumor; Cytokines; Female; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Lysophospholipids; Ovarian Neoplasms; Pertussis Toxin; Receptors, G-Protein-Coupled; Receptors, Lysophosphatidic Acid | 2004 |
Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors.
Topics: Adenosine Diphosphate Ribose; Female; Gonadotropin-Releasing Hormone; GTP-Binding Proteins; Humans; Immunoblotting; Leiomyoma; Ovarian Neoplasms; Pertussis Toxin; Receptors, LHRH; Uterine Neoplasms; Virulence Factors, Bordetella | 1996 |
Functional overexpression of human poly(ADP-ribose) polymerase in transfected rat tumor cells.
Topics: Adenosine Diphosphate Ribose; Animals; Cell Survival; Cisplatin; Female; Humans; Methylnitronitrosoguanidine; Ovarian Neoplasms; Poly(ADP-ribose) Polymerases; Rats; Transfection; Tumor Cells, Cultured | 1997 |
Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Topics: Adenosine Diphosphate Ribose; Alternative Splicing; Base Sequence; Cell Division; Endometrial Neoplasms; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression; Genes, fos; Gonadotropin-Releasing Hormone; GTP-Binding Protein alpha Subunits, Gi-Go; GTP-Binding Proteins; Humans; Molecular Sequence Data; Mutation; Ovarian Neoplasms; Pertussis Toxin; Phosphorylation; Phosphotyrosine; Protein Tyrosine Phosphatases; Receptors, LHRH; RNA, Messenger; Sequence Analysis, DNA; Signal Transduction; Tumor Cells, Cultured; Virulence Factors, Bordetella | 2001 |